Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Дистанционное мониторирование электрокардиограммы у онкологических пациентов как метод выявления кардиотоксичности: клинический случай - Журнал Терапевтический архив №4 Вопросы диагностики внутренних болезней 2024
Дистанционное мониторирование электрокардиограммы у онкологических пациентов как метод выявления кардиотоксичности: клинический случай
Меситская Д.Ф., Яснева А.С., Фашафша З.З., Копылов Ф.Ю., Андреев Д.А. Дистанционное мониторирование электрокардиограммы у онкологических пациентов как метод выявления кардиотоксичности: клинический случай. Терапевтический архив. 2024;96(4):386–390. DOI: 10.26442/00403660.2024.04.202607
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
2024;96(4):386–390. DOI: 10.26442/00403660.2024.04.202607
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
2024;96(4):386–390. DOI: 10.26442/00403660.2024.04.202607
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Кардиотоксичность – прямое неблагоприятное воздействие противораковых препаратов на функцию или структуру сердца, возникающее как во время лечения, так и через много лет после него. Проявления кардиотоксичности могут быть самыми различными: сердечная недостаточность, ишемическая болезнь сердца, кардиомиопатия, миокардит, перикардит и аритмии, в том числе фибрилляция предсердий (ФП). Частота выявления ФП в популяции онкологических пациентов, проходящих терапию, составляет 20–30%. Современные возможности дистанционного мониторинга электрокардиограммы обеспечивают своевременное выявление и лечение ФП у онкологических пациентов, в том числе назначение антикоагулянтов. В статье представлен клинический случай пациента 59 лет с плоскоклеточным раком нижней трети пищевода, у которого после 1-го курса полихимиотерапии по схеме TPF (доцетаксел, цисплатин, 5-фторурацил) выявлена ФП с помощью одноканального монитора электрокардиограммы в чехле смартфона.
Ключевые слова: кардиотоксичность, дистанционное мониторирование, химиотерапия, антикоагулянты
Keywords: cardiotoxicity, remote monitoring, chemotherapy, anticoagulants
Ключевые слова: кардиотоксичность, дистанционное мониторирование, химиотерапия, антикоагулянты
________________________________________________
Keywords: cardiotoxicity, remote monitoring, chemotherapy, anticoagulants
Полный текст
Список литературы
1. Xiao D, Li J, Liu Y, et al. Emerging trends and hotspots evolution in cardiotoxicity: A bibliometric and knowledge-Map analysis From 2010 to 2022. Front Cardiovasc Med. 2023;10:1089916. DOI:10.3389/fcvm.2023.1089916
2. Hajjar LA, Fonseca SMR, Machado TIV. Atrial fibrillation and cancer. Front Cardiovasc Med. 2021;8:590768. DOI:10.3389/fcvm.2021.590768
3. Jakobsen CB, Lamberts M, Carlson N, et al. Incidence of atrial fibrillation in different major cancer subtypes: A Nationwide population-based 12 year follow up study. BMC Cancer. 2019;19(1):1105. DOI:10.1186/s12885-019-6314-9
4. Lancellotti P, Marechal P, Donis N, Oury C. Inflammation, cardiovascular disease, and cancer: A common link with far-reaching implications. Eur Heart J. 2019;40(48):3910-2. DOI:10.1093/eurheartj/ehz645
5. Alexandre J, Salem JE, Moslehi J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312-20. DOI:10.1093/ehjcvp/pvaa037
6. Herrmann J. Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474-502. DOI:10.1038/s41569-020-0348-1
7. Ahmad J, Thurlapati A, Thotamgari S, et al. Anti-cancer drugs associated atrial fibrillation-an analysis of real-world pharmacovigilance data. Front Cardiovasc Med. 2022;9:739044. DOI:10.3389/fcvm.2022.739044
8. Riess H, Ay C, Bauersachs R, et al. Use of direct oral anticoagulants in patients with cancer: Practical considerations for the management of patients with nausea or vomiting. Oncologist. 2018;23(7):822-39. DOI:10.1634/theoncologist.2017-0473
9. Grymonprez M, De Backer TL, Bertels X, et al. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Front Pharmacol. 2023;14:1125576. DOI:10.3389/fphar.2023.1125576
10. Ording AG, Horváth-Puhó E, Adelborg K, et al. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: A Danish nationwide population-based cohort study. Cancer Med. 2017;6(6):1165-72. DOI:10.1002/cam4.1054
11. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019;94(7):780-5. DOI:10.1002/ajh.25494
12. Wu VC, Wang CL, Huang YT, et al. Novel oral anticoagulant versus warfarin in cancerpatients with atrial fibrillation: An 8-year population-based cohort study. J Cancer. 2020;11:92-9. DOI:10.7150/jca.36468
13. Deng Y, Tong Y, Deng Y, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: A systematic review and meta-analysis. J Am Heart Assoc. 2019;8(14):e012540. DOI:10.1161/JAHA.119.012540
14. Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: A study-level metaanalysis. Thromb Haemost. 2020;120(2):314-21. DOI:10.1055/s-0039-3400300
15. Sawant AC, Kumar A, McCray W, et al. Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: A national veterans affairs database study. J Geriatr Cardiol. 2019;16(9):706-9. DOI:10.11909%2Fj.issn.1671-5411.2019.09.006
16. Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2(3):200-9. DOI:10.1182/bloodadvances.2017010694
17. Melloni C, Dunning A, Granger CB, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: Insights from the ARISTOTLE Trial. Am J Med. 2017;130(12):1440-48.e1. DOI:10.1016/j.amjmed.2017.06.026
18. Haverkamp HT, Fosse SO, Schuster P. Accuracy and usability of single-lead ECG from smartphones – A clinical study. Indian Pacing Electrophysiol J. 2019;19(4):145-9. DOI:10.1016/j.ipej.2019.02.006
19. Manetas-Stavrakakis N, Sotiropoulou IM, Paraskevas T, et al. Accuracy of artificial intelligence-based technologies for the diagnosis of atrial fibrillation: A systematic review and meta-analysis. J Clin Med. 2023;12(20):6576. DOI:10.3390/jcm12206576
20. Badheeb AM, Ahmed F, Alzahrani HA, et al. Cancer therapy-related cardiotoxicity: A comprehensive retrospective analysis at Najran Cancer Center, Saudi Arabia. Cureus. 2023;15(7):e41287. DOI:10.7759/cureus.41287
21. Costa IBSDS, Bittar CS, Fonseca SMR, et al. Brazilian cardio-oncology: The 10-year experience of the Instituto do Cancer do Estado de Sao Paulo. BMC Cardiovasc Disord. 2020;20(1):206. DOI:10.1186/s12872-020-01471-8
22. Brandão SR, Carvalho F, Amado F, et al. Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. Metabolism. 2022;134:155250. DOI:10.1016/j.metabol.2022.155250
23. Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract (1995). 2019;47(1):6-15. DOI:10.1080/21548331.2018.1530831
24. Alexandre J, Boismoreau L, Morice PM, et al. Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials. JACC CardioOncol. 2023;5(2):216-26. DOI:10.1016/j.jaccao.2022.11.019
25. Adhikari A, Asdaq SMB, Al Hawaj MA, et al. Anticancer drug-induced cardiotoxicity: Insights and pharmacogenetics. Pharmaceuticals (Basel). 2021;14(10):970. DOI:10.3390/ph14100970
26. Lobenwein D, Kocher F, Dobner S, et al. Cardiotoxic mechanisms of cancer immunotherapy – A systematic review. Int J Cardiol. 2021;323:179-87. DOI:10.1016/j.ijcard.2020.08.033
27. Moriyama S, Yokoyama T, Irie K, et al. Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. J Cardiol Cases. 2019;20(5):183-6. DOI:10.1016/j.jccase.2019.08.005
28. Peng H, Chen B, He S, et al. Efficacy and toxicity of three induction chemotherapy regimens in locoregionally advanced nasopharyngeal carcinoma: Outcomes of 10-year follow-up. Front Oncol. 2021;11:765378. DOI:10.3389/fonc.2021.765378
29. Diederichsen SZ, Haugan KJ, Brandes A, et al. Natural history of subclinical atrial fibrillation detected by implanted loop recorders. J Am Coll Cardiol. 2019;74(22):2771-81. DOI:10.1016/j.jacc.2019.09.050
30. Gognieva D, Vishnyakova N, Mitina Y, et al. Remote screening for atrial fibrillation by a federal cardiac monitoring system in primary care patients in Russia: Results from the Prospective Interventional Multicenter FECAS-AFS Study. Glob Heart. 2022;17(1):4. DOI:10.5334/gh.1057
2. Hajjar LA, Fonseca SMR, Machado TIV. Atrial fibrillation and cancer. Front Cardiovasc Med. 2021;8:590768. DOI:10.3389/fcvm.2021.590768
3. Jakobsen CB, Lamberts M, Carlson N, et al. Incidence of atrial fibrillation in different major cancer subtypes: A Nationwide population-based 12 year follow up study. BMC Cancer. 2019;19(1):1105. DOI:10.1186/s12885-019-6314-9
4. Lancellotti P, Marechal P, Donis N, Oury C. Inflammation, cardiovascular disease, and cancer: A common link with far-reaching implications. Eur Heart J. 2019;40(48):3910-2. DOI:10.1093/eurheartj/ehz645
5. Alexandre J, Salem JE, Moslehi J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312-20. DOI:10.1093/ehjcvp/pvaa037
6. Herrmann J. Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474-502. DOI:10.1038/s41569-020-0348-1
7. Ahmad J, Thurlapati A, Thotamgari S, et al. Anti-cancer drugs associated atrial fibrillation-an analysis of real-world pharmacovigilance data. Front Cardiovasc Med. 2022;9:739044. DOI:10.3389/fcvm.2022.739044
8. Riess H, Ay C, Bauersachs R, et al. Use of direct oral anticoagulants in patients with cancer: Practical considerations for the management of patients with nausea or vomiting. Oncologist. 2018;23(7):822-39. DOI:10.1634/theoncologist.2017-0473
9. Grymonprez M, De Backer TL, Bertels X, et al. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Front Pharmacol. 2023;14:1125576. DOI:10.3389/fphar.2023.1125576
10. Ording AG, Horváth-Puhó E, Adelborg K, et al. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: A Danish nationwide population-based cohort study. Cancer Med. 2017;6(6):1165-72. DOI:10.1002/cam4.1054
11. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019;94(7):780-5. DOI:10.1002/ajh.25494
12. Wu VC, Wang CL, Huang YT, et al. Novel oral anticoagulant versus warfarin in cancerpatients with atrial fibrillation: An 8-year population-based cohort study. J Cancer. 2020;11:92-9. DOI:10.7150/jca.36468
13. Deng Y, Tong Y, Deng Y, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: A systematic review and meta-analysis. J Am Heart Assoc. 2019;8(14):e012540. DOI:10.1161/JAHA.119.012540
14. Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: A study-level metaanalysis. Thromb Haemost. 2020;120(2):314-21. DOI:10.1055/s-0039-3400300
15. Sawant AC, Kumar A, McCray W, et al. Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: A national veterans affairs database study. J Geriatr Cardiol. 2019;16(9):706-9. DOI:10.11909%2Fj.issn.1671-5411.2019.09.006
16. Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2(3):200-9. DOI:10.1182/bloodadvances.2017010694
17. Melloni C, Dunning A, Granger CB, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: Insights from the ARISTOTLE Trial. Am J Med. 2017;130(12):1440-48.e1. DOI:10.1016/j.amjmed.2017.06.026
18. Haverkamp HT, Fosse SO, Schuster P. Accuracy and usability of single-lead ECG from smartphones – A clinical study. Indian Pacing Electrophysiol J. 2019;19(4):145-9. DOI:10.1016/j.ipej.2019.02.006
19. Manetas-Stavrakakis N, Sotiropoulou IM, Paraskevas T, et al. Accuracy of artificial intelligence-based technologies for the diagnosis of atrial fibrillation: A systematic review and meta-analysis. J Clin Med. 2023;12(20):6576. DOI:10.3390/jcm12206576
20. Badheeb AM, Ahmed F, Alzahrani HA, et al. Cancer therapy-related cardiotoxicity: A comprehensive retrospective analysis at Najran Cancer Center, Saudi Arabia. Cureus. 2023;15(7):e41287. DOI:10.7759/cureus.41287
21. Costa IBSDS, Bittar CS, Fonseca SMR, et al. Brazilian cardio-oncology: The 10-year experience of the Instituto do Cancer do Estado de Sao Paulo. BMC Cardiovasc Disord. 2020;20(1):206. DOI:10.1186/s12872-020-01471-8
22. Brandão SR, Carvalho F, Amado F, et al. Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. Metabolism. 2022;134:155250. DOI:10.1016/j.metabol.2022.155250
23. Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract (1995). 2019;47(1):6-15. DOI:10.1080/21548331.2018.1530831
24. Alexandre J, Boismoreau L, Morice PM, et al. Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials. JACC CardioOncol. 2023;5(2):216-26. DOI:10.1016/j.jaccao.2022.11.019
25. Adhikari A, Asdaq SMB, Al Hawaj MA, et al. Anticancer drug-induced cardiotoxicity: Insights and pharmacogenetics. Pharmaceuticals (Basel). 2021;14(10):970. DOI:10.3390/ph14100970
26. Lobenwein D, Kocher F, Dobner S, et al. Cardiotoxic mechanisms of cancer immunotherapy – A systematic review. Int J Cardiol. 2021;323:179-87. DOI:10.1016/j.ijcard.2020.08.033
27. Moriyama S, Yokoyama T, Irie K, et al. Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. J Cardiol Cases. 2019;20(5):183-6. DOI:10.1016/j.jccase.2019.08.005
28. Peng H, Chen B, He S, et al. Efficacy and toxicity of three induction chemotherapy regimens in locoregionally advanced nasopharyngeal carcinoma: Outcomes of 10-year follow-up. Front Oncol. 2021;11:765378. DOI:10.3389/fonc.2021.765378
29. Diederichsen SZ, Haugan KJ, Brandes A, et al. Natural history of subclinical atrial fibrillation detected by implanted loop recorders. J Am Coll Cardiol. 2019;74(22):2771-81. DOI:10.1016/j.jacc.2019.09.050
30. Gognieva D, Vishnyakova N, Mitina Y, et al. Remote screening for atrial fibrillation by a federal cardiac monitoring system in primary care patients in Russia: Results from the Prospective Interventional Multicenter FECAS-AFS Study. Glob Heart. 2022;17(1):4. DOI:10.5334/gh.1057
2. Hajjar LA, Fonseca SMR, Machado TIV. Atrial fibrillation and cancer. Front Cardiovasc Med. 2021;8:590768. DOI:10.3389/fcvm.2021.590768
3. Jakobsen CB, Lamberts M, Carlson N, et al. Incidence of atrial fibrillation in different major cancer subtypes: A Nationwide population-based 12 year follow up study. BMC Cancer. 2019;19(1):1105. DOI:10.1186/s12885-019-6314-9
4. Lancellotti P, Marechal P, Donis N, Oury C. Inflammation, cardiovascular disease, and cancer: A common link with far-reaching implications. Eur Heart J. 2019;40(48):3910-2. DOI:10.1093/eurheartj/ehz645
5. Alexandre J, Salem JE, Moslehi J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312-20. DOI:10.1093/ehjcvp/pvaa037
6. Herrmann J. Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474-502. DOI:10.1038/s41569-020-0348-1
7. Ahmad J, Thurlapati A, Thotamgari S, et al. Anti-cancer drugs associated atrial fibrillation-an analysis of real-world pharmacovigilance data. Front Cardiovasc Med. 2022;9:739044. DOI:10.3389/fcvm.2022.739044
8. Riess H, Ay C, Bauersachs R, et al. Use of direct oral anticoagulants in patients with cancer: Practical considerations for the management of patients with nausea or vomiting. Oncologist. 2018;23(7):822-39. DOI:10.1634/theoncologist.2017-0473
9. Grymonprez M, De Backer TL, Bertels X, et al. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Front Pharmacol. 2023;14:1125576. DOI:10.3389/fphar.2023.1125576
10. Ording AG, Horváth-Puhó E, Adelborg K, et al. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: A Danish nationwide population-based cohort study. Cancer Med. 2017;6(6):1165-72. DOI:10.1002/cam4.1054
11. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019;94(7):780-5. DOI:10.1002/ajh.25494
12. Wu VC, Wang CL, Huang YT, et al. Novel oral anticoagulant versus warfarin in cancerpatients with atrial fibrillation: An 8-year population-based cohort study. J Cancer. 2020;11:92-9. DOI:10.7150/jca.36468
13. Deng Y, Tong Y, Deng Y, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: A systematic review and meta-analysis. J Am Heart Assoc. 2019;8(14):e012540. DOI:10.1161/JAHA.119.012540
14. Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: A study-level metaanalysis. Thromb Haemost. 2020;120(2):314-21. DOI:10.1055/s-0039-3400300
15. Sawant AC, Kumar A, McCray W, et al. Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: A national veterans affairs database study. J Geriatr Cardiol. 2019;16(9):706-9. DOI:10.11909%2Fj.issn.1671-5411.2019.09.006
16. Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2(3):200-9. DOI:10.1182/bloodadvances.2017010694
17. Melloni C, Dunning A, Granger CB, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: Insights from the ARISTOTLE Trial. Am J Med. 2017;130(12):1440-48.e1. DOI:10.1016/j.amjmed.2017.06.026
18. Haverkamp HT, Fosse SO, Schuster P. Accuracy and usability of single-lead ECG from smartphones – A clinical study. Indian Pacing Electrophysiol J. 2019;19(4):145-9. DOI:10.1016/j.ipej.2019.02.006
19. Manetas-Stavrakakis N, Sotiropoulou IM, Paraskevas T, et al. Accuracy of artificial intelligence-based technologies for the diagnosis of atrial fibrillation: A systematic review and meta-analysis. J Clin Med. 2023;12(20):6576. DOI:10.3390/jcm12206576
20. Badheeb AM, Ahmed F, Alzahrani HA, et al. Cancer therapy-related cardiotoxicity: A comprehensive retrospective analysis at Najran Cancer Center, Saudi Arabia. Cureus. 2023;15(7):e41287. DOI:10.7759/cureus.41287
21. Costa IBSDS, Bittar CS, Fonseca SMR, et al. Brazilian cardio-oncology: The 10-year experience of the Instituto do Cancer do Estado de Sao Paulo. BMC Cardiovasc Disord. 2020;20(1):206. DOI:10.1186/s12872-020-01471-8
22. Brandão SR, Carvalho F, Amado F, et al. Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. Metabolism. 2022;134:155250. DOI:10.1016/j.metabol.2022.155250
23. Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract (1995). 2019;47(1):6-15. DOI:10.1080/21548331.2018.1530831
24. Alexandre J, Boismoreau L, Morice PM, et al. Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials. JACC CardioOncol. 2023;5(2):216-26. DOI:10.1016/j.jaccao.2022.11.019
25. Adhikari A, Asdaq SMB, Al Hawaj MA, et al. Anticancer drug-induced cardiotoxicity: Insights and pharmacogenetics. Pharmaceuticals (Basel). 2021;14(10):970. DOI:10.3390/ph14100970
26. Lobenwein D, Kocher F, Dobner S, et al. Cardiotoxic mechanisms of cancer immunotherapy – A systematic review. Int J Cardiol. 2021;323:179-87. DOI:10.1016/j.ijcard.2020.08.033
27. Moriyama S, Yokoyama T, Irie K, et al. Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. J Cardiol Cases. 2019;20(5):183-6. DOI:10.1016/j.jccase.2019.08.005
28. Peng H, Chen B, He S, et al. Efficacy and toxicity of three induction chemotherapy regimens in locoregionally advanced nasopharyngeal carcinoma: Outcomes of 10-year follow-up. Front Oncol. 2021;11:765378. DOI:10.3389/fonc.2021.765378
29. Diederichsen SZ, Haugan KJ, Brandes A, et al. Natural history of subclinical atrial fibrillation detected by implanted loop recorders. J Am Coll Cardiol. 2019;74(22):2771-81. DOI:10.1016/j.jacc.2019.09.050
30. Gognieva D, Vishnyakova N, Mitina Y, et al. Remote screening for atrial fibrillation by a federal cardiac monitoring system in primary care patients in Russia: Results from the Prospective Interventional Multicenter FECAS-AFS Study. Glob Heart. 2022;17(1):4. DOI:10.5334/gh.1057
________________________________________________
2. Hajjar LA, Fonseca SMR, Machado TIV. Atrial fibrillation and cancer. Front Cardiovasc Med. 2021;8:590768. DOI:10.3389/fcvm.2021.590768
3. Jakobsen CB, Lamberts M, Carlson N, et al. Incidence of atrial fibrillation in different major cancer subtypes: A Nationwide population-based 12 year follow up study. BMC Cancer. 2019;19(1):1105. DOI:10.1186/s12885-019-6314-9
4. Lancellotti P, Marechal P, Donis N, Oury C. Inflammation, cardiovascular disease, and cancer: A common link with far-reaching implications. Eur Heart J. 2019;40(48):3910-2. DOI:10.1093/eurheartj/ehz645
5. Alexandre J, Salem JE, Moslehi J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312-20. DOI:10.1093/ehjcvp/pvaa037
6. Herrmann J. Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474-502. DOI:10.1038/s41569-020-0348-1
7. Ahmad J, Thurlapati A, Thotamgari S, et al. Anti-cancer drugs associated atrial fibrillation-an analysis of real-world pharmacovigilance data. Front Cardiovasc Med. 2022;9:739044. DOI:10.3389/fcvm.2022.739044
8. Riess H, Ay C, Bauersachs R, et al. Use of direct oral anticoagulants in patients with cancer: Practical considerations for the management of patients with nausea or vomiting. Oncologist. 2018;23(7):822-39. DOI:10.1634/theoncologist.2017-0473
9. Grymonprez M, De Backer TL, Bertels X, et al. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Front Pharmacol. 2023;14:1125576. DOI:10.3389/fphar.2023.1125576
10. Ording AG, Horváth-Puhó E, Adelborg K, et al. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: A Danish nationwide population-based cohort study. Cancer Med. 2017;6(6):1165-72. DOI:10.1002/cam4.1054
11. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019;94(7):780-5. DOI:10.1002/ajh.25494
12. Wu VC, Wang CL, Huang YT, et al. Novel oral anticoagulant versus warfarin in cancerpatients with atrial fibrillation: An 8-year population-based cohort study. J Cancer. 2020;11:92-9. DOI:10.7150/jca.36468
13. Deng Y, Tong Y, Deng Y, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: A systematic review and meta-analysis. J Am Heart Assoc. 2019;8(14):e012540. DOI:10.1161/JAHA.119.012540
14. Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: A study-level metaanalysis. Thromb Haemost. 2020;120(2):314-21. DOI:10.1055/s-0039-3400300
15. Sawant AC, Kumar A, McCray W, et al. Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: A national veterans affairs database study. J Geriatr Cardiol. 2019;16(9):706-9. DOI:10.11909%2Fj.issn.1671-5411.2019.09.006
16. Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2(3):200-9. DOI:10.1182/bloodadvances.2017010694
17. Melloni C, Dunning A, Granger CB, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: Insights from the ARISTOTLE Trial. Am J Med. 2017;130(12):1440-48.e1. DOI:10.1016/j.amjmed.2017.06.026
18. Haverkamp HT, Fosse SO, Schuster P. Accuracy and usability of single-lead ECG from smartphones – A clinical study. Indian Pacing Electrophysiol J. 2019;19(4):145-9. DOI:10.1016/j.ipej.2019.02.006
19. Manetas-Stavrakakis N, Sotiropoulou IM, Paraskevas T, et al. Accuracy of artificial intelligence-based technologies for the diagnosis of atrial fibrillation: A systematic review and meta-analysis. J Clin Med. 2023;12(20):6576. DOI:10.3390/jcm12206576
20. Badheeb AM, Ahmed F, Alzahrani HA, et al. Cancer therapy-related cardiotoxicity: A comprehensive retrospective analysis at Najran Cancer Center, Saudi Arabia. Cureus. 2023;15(7):e41287. DOI:10.7759/cureus.41287
21. Costa IBSDS, Bittar CS, Fonseca SMR, et al. Brazilian cardio-oncology: The 10-year experience of the Instituto do Cancer do Estado de Sao Paulo. BMC Cardiovasc Disord. 2020;20(1):206. DOI:10.1186/s12872-020-01471-8
22. Brandão SR, Carvalho F, Amado F, et al. Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. Metabolism. 2022;134:155250. DOI:10.1016/j.metabol.2022.155250
23. Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract (1995). 2019;47(1):6-15. DOI:10.1080/21548331.2018.1530831
24. Alexandre J, Boismoreau L, Morice PM, et al. Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials. JACC CardioOncol. 2023;5(2):216-26. DOI:10.1016/j.jaccao.2022.11.019
25. Adhikari A, Asdaq SMB, Al Hawaj MA, et al. Anticancer drug-induced cardiotoxicity: Insights and pharmacogenetics. Pharmaceuticals (Basel). 2021;14(10):970. DOI:10.3390/ph14100970
26. Lobenwein D, Kocher F, Dobner S, et al. Cardiotoxic mechanisms of cancer immunotherapy – A systematic review. Int J Cardiol. 2021;323:179-87. DOI:10.1016/j.ijcard.2020.08.033
27. Moriyama S, Yokoyama T, Irie K, et al. Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. J Cardiol Cases. 2019;20(5):183-6. DOI:10.1016/j.jccase.2019.08.005
28. Peng H, Chen B, He S, et al. Efficacy and toxicity of three induction chemotherapy regimens in locoregionally advanced nasopharyngeal carcinoma: Outcomes of 10-year follow-up. Front Oncol. 2021;11:765378. DOI:10.3389/fonc.2021.765378
29. Diederichsen SZ, Haugan KJ, Brandes A, et al. Natural history of subclinical atrial fibrillation detected by implanted loop recorders. J Am Coll Cardiol. 2019;74(22):2771-81. DOI:10.1016/j.jacc.2019.09.050
30. Gognieva D, Vishnyakova N, Mitina Y, et al. Remote screening for atrial fibrillation by a federal cardiac monitoring system in primary care patients in Russia: Results from the Prospective Interventional Multicenter FECAS-AFS Study. Glob Heart. 2022;17(1):4. DOI:10.5334/gh.1057
Авторы
Д.Ф. Меситская*, А.С. Яснева, З.З. Фашафша, Ф.Ю. Копылов, Д.А. Андреев
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*aranid980@gmail.com
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*aranid980@gmail.com
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*aranid980@gmail.com
________________________________________________
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*aranid980@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.